Quick Answer
Edgewise Therapeutics, Inc. reported Research And Development Expense of $151.39 million for the year ending 2025.
- Edgewise Therapeutics, Inc. showed an increase of +19.2% in Research And Development Expense from 2024 to 2025.
- This data is from Edgewise Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $2.97 million | Q2 2020: $3.64 million | Q3 2020: $3.24 million | Q1 2021: $5.36 million | Q2 2021: $7.86 million | Q3 2021: $9.88 million | Q1 2022: $11.12 million | Q2 2022: $12.40 million | Q3 2022: $13.89 million | Q1 2023: $19.88 million | Q2 2023: $19.56 million | Q3 2023: $23.79 million | Q1 2024: $27.69 million | Q2 2024: $30.68 million | Q3 2024: $32.22 million | Q1 2025: $36.76 million | Q2 2025: $33.56 million | Q3 2025: $37.48 million.
- Over the full 6 years of available data (2020 to 2025), Edgewise Therapeutics, Inc.'s Research And Development Expense has grown by 910.4%.
- Historical annual values: Fiscal year 2025: $151.39 million | Fiscal year 2024: $126.97 million | Fiscal year 2023: $90.91 million | Fiscal year 2022: $54.03 million | Fiscal year 2021: $32.19 million | Fiscal year 2020: $14.98 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: